# Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation

> **NCT01472783** · PHASE1,PHASE2 · COMPLETED · sponsor: **Vejle Hospital** · enrollment: 49 (actual)

## Conditions studied

- Recurrent, Epithelial Ovarian Cancer

## Interventions

- **DRUG:** Veliparib

## Key facts

- **NCT ID:** NCT01472783
- **Lead sponsor:** Vejle Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2016-01
- **Final completion:** 2016-08
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2016-11-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01472783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01472783, "Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01472783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*